top of page
Search

Tech Transfer in Biologics: Where Promises Meet Performance

  • Writer: Sarah Sink
    Sarah Sink
  • Nov 6, 2025
  • 3 min read

Tech transfer is often described as a “handoff.” In reality, it is a tightrope walk that determines whether a biologic program stays balanced or stumbles under pressure.


For protein-based biologics, each transfer from development to manufacturing is a test of coordination, communication, and control. You are not just moving a process. You are moving a living system that responds to every change you make.



More Than a Document Exchange


A successful tech transfer is not about passing binders or uploading protocols. It is about translating process knowledge so that performance can be reproduced, not just replicated.


In biologics, small changes can create big consequences. Slight differences in agitation speed, temperature, or buffer preparation can alter folding, yield, and stability. The challenge is not simply to repeat steps but to understand what makes the process perform.


That level of precision takes more than good documentation. It takes collaboration.



The Quiet Risks in Protein Transfers


What often surprises biotech teams is that what worked in development does not always behave the same in GMP manufacturing. Proteins can aggregate, purification yields can shift, and hold times can affect quality.


These challenges usually trace back to communication gaps.


  • The sending site may not fully explain why certain parameters were chosen.

  • The receiving site may interpret data differently.

  • Analytical methods may look identical on paper but perform differently in practice.


Each of these small gaps can snowball into deviations, investigations, and rework. In biologics, where materials are expensive and timelines are tight, the smallest oversight can delay progress by months.



Where the Best Programs Get It Right


The best biotech programs treat tech transfer as a living partnership, not a checklist.


That means involving analytical, formulation, and process SMEs from both the sending and receiving teams early in the process. It is not enough to align on what is being transferred. Both sides need to align on why certain parameters matter, how data will be interpreted, and what flexibility exists when something behaves differently at scale.


Here is what success looks like:


  • Open communication: Teams share not just data but context.

  • Shared accountability: Both sides own the outcome, not just the tasks.

  • Adaptability: When something shifts, teams collaborate to adjust rather than escalate.


When biotech and CDMO teams work together this way, issues are identified earlier and resolved faster, and the molecule moves forward more smoothly.



The Business Development Perspective


For business development professionals, tech transfer is where partnerships are proven. It is easy to align on pricing, scope, and capacity. The real test comes when science meets execution.


Strong BD professionals help ensure their CDMO partners have the right structure to support collaborative execution. That includes making sure:


  • SMEs from both sides are involved from the beginning.

  • Risks are clearly defined, documented, and revisited throughout the project.

  • Communication plans are transparent and updated as the process evolves.


CDMOs that foster this kind of open collaboration are the ones that turn complex programs into repeat business. They are not just service providers. They are strategic partners who understand that the molecule’s success is shared.



What Biotech Teams Should Look For


If your biotech team is evaluating CDMOs for a protein-based program, ask questions that uncover how they manage tech transfer:


  • Who owns risk if a process behaves differently at scale?

  • How is analytical comparability ensured across sites?

  • How do your teams communicate between development, QC, and manufacturing?


You are not only choosing a facility. You are choosing how your science will be interpreted and executed under pressure.



Final Thoughts


Tech transfer is the bridge between potential and performance. For protein-based biologics, precision and partnership matter more than anything else. The best outcomes happen when biotech and CDMO teams communicate openly, share context, and solve problems together.


If your team is preparing for a transfer or comparing CDMOs for biologic manufacturing, my guide, How to Compare CDMO Quotes: 10 Factors Beyond Cost, can help you spot alignment early. It walks through how to evaluate proposals and identify which partners are truly equipped to support collaborative, transparent tech transfers.


Because in biologics, success depends on more than the science. It depends on how well you and your partner bring that science to life.



For more insights and personalized support in navigating the biotech-CDMO landscape, visit www.yourpharmagirl.com and follow Your Pharma Girl on LinkedIn. Whether you need strategic guidance, tailored BD solutions, or expert advice on building lasting partnerships, I am here to help you and your team succeed at every stage of development.

 
 
 

Comments

bottom of page